From the FDA Drug Label
Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia and dizziness. The FDA drug label for semaglutide (OZEMPIC) indicates that fatigue is an adverse reaction associated with the medication, with a frequency of more than 0.4% 1.
From the Research
Fatigue is a common side effect of Wegovy (semaglutide), but the provided evidence does not directly address the relationship between Wegovy and fatigue, so the management of fatigue should focus on general strategies to mitigate its impact. When considering the management of fatigue in patients taking Wegovy, it's essential to prioritize strategies that can help mitigate its effects without compromising the benefits of the medication for weight management and metabolic health. Given the lack of direct evidence from the provided studies, the approach should be based on general principles of managing side effects and optimizing patient outcomes. Some key considerations include:
- Staying well-hydrated
- Maintaining adequate protein intake (at least 0.8g per kg of body weight daily)
- Ensuring sufficient electrolyte intake, particularly sodium, potassium, and magnesium
- Consistent timing of injections to minimize variability in medication effects If fatigue becomes severe or persists, consulting a healthcare provider is crucial for personalized advice, which may include adjusting the dose, recommending supplements, or investigating other potential causes of fatigue 2. It's also important to note that while Vitamin B12 deficiency can cause fatigue, the effectiveness of Vitamin B12 supplementation in improving fatigue, cognitive function, and depressive symptoms in patients without overt Vitamin B12 deficiency is uncertain 3. Therefore, any decision to supplement should be made under medical guidance, considering the individual patient's needs and deficiencies. Given the recent study on semaglutide's real-world impact on weight, HbA1c, and healthcare resource utilization 2, the benefits of Wegovy for weight management and metabolic health should be weighed against the temporary side effects, and patients should not stop taking the medication without medical guidance.